The Conversation (0)
CanniMed Therapeutics released its unaudited financial results of operations for the three months ended January 31, 2018.
CanniMed Therapeutics (TSX:CMED) released its unaudited financial results of operations for the three months ended January 31, 2018.
As quoted in the press release:
“CanniMed’s continued success reflects our accomplished team that always strives for excellence and remains focused on high-quality products from GMP compliant production practices,” said Brent Zettl, CEO, CanniMed. “This past quarter we have met many key milestones, including new product introduction and capacity growth. Now, as CanniMed transitions and integrates with Aurora Cannabis, I am confident that our tremendous people will continue to serve our customers well and help Aurora to realize even greater accomplishments.”
Aurora Successful in Bid for CanniMed Therapeutics Through Take-Up of Shares
On March 15, 2018, Aurora Cannabis Inc. (“Aurora”) announced that it had completed its initial take up of common shares of the Company pursuant to its offer to purchase all of the issued and outstanding CanniMed shares (the “Offer”). Together with shares purchased in the market, the shares taken up represent 86.8% of the total outstanding shares of the Company on a fully diluted basis. Pursuant to applicable Canadian securities laws requiring Aurora to extend its Offer, Aurora extended the period in which shareholders of CanniMed may tender their shares under the Offer to March 25, 2018.
Click here to read the full press release.
Source: marijuanaindex.com
